The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2019 | Clinical impact of ATM and TP53 mutations in mantle cell lymphoma
Jitka Malčíková, PhD, Masaryk University, Brno, Czech Republic, talks about a paper recently published in Leukemia & Lymphoma on ataxia-telangiectasia mutated (ATM) and TP53 mutations in mantle cell lymphoma. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
